Advertisement
U.S. markets open in 29 minutes
  • S&P Futures

    5,306.00
    -2.25 (-0.04%)
     
  • Dow Futures

    40,173.00
    +29.00 (+0.07%)
     
  • Nasdaq Futures

    18,484.50
    -19.25 (-0.10%)
     
  • Russell 2000 Futures

    2,140.60
    +2.20 (+0.10%)
     
  • Crude Oil

    82.68
    +1.33 (+1.63%)
     
  • Gold

    2,230.80
    +18.10 (+0.82%)
     
  • Silver

    24.73
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0821
    -0.0008 (-0.08%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2652
    +0.0014 (+0.11%)
     
  • USD/JPY

    151.1920
    -0.0540 (-0.04%)
     
  • Bitcoin USD

    70,638.80
    +489.09 (+0.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.45
    +20.47 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XENT, RMED and EROS

NEW YORK, NY / ACCESSWIRE / July 2, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Intersect ENT, Inc. (XENT)
Class Period: August 1, 2018 to May 6, 2019
Lead Plaintiff Deadline: July 15, 2019

The complaint alleges that during the class period Intersect ENT, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the XENT lawsuit: http://www.kleinstocklaw.com/pslra-1/intersect-ent-inc-loss-submission-form?id=2212&from=1

Ra Medical Systems, Inc. (RMED)
Class Period: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company's September 2018 initial public offering.
Lead Plaintiff Deadline: August 6, 2019

During the class period, Ra Medical Systems, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's evaluation of sales personnel candidates was inadequate; (2) the Company's training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company's manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the RMED lawsuit: http://www.kleinstocklaw.com/pslra-1/ra-medical-systems-inc-loss-submission-form?id=2212&from=1

Eros International Plc (EROS)
Class Period: July 28, 2017 to June 5, 2019
Lead Plaintiff Deadline: August 20, 2019

Eros International Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party
transactions to fabricate receivables that they reported in Eros's public financial disclosures; (2) because of this scheme, Eros's financial position was weaker than what the Company disclosed; (3) consequently, the Company's Indian subsidiary, Eros International Media Ltd ("EIML"), missed loan payments and had its credit
downgraded; and (4) due to the foregoing, Defendants' statements about Eros's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the EROS lawsuit: http://www.kleinstocklaw.com/pslra-1/eros-international-plc-loss-submission-form?id=2212&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/550708/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-XENT-RMED-and-EROS

Advertisement